34,237 Shares in IDEAYA Biosciences, Inc. $IDYA Bought by Fifth Lane Capital LP

Fifth Lane Capital LP acquired a new position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the third quarter, Holdings Channel.com reports. The firm acquired 34,237 shares of the company’s stock, valued at approximately $932,000. IDEAYA Biosciences makes up approximately 0.8% of Fifth Lane Capital LP’s portfolio, making the stock its 25th biggest position.

Other large investors also recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of IDEAYA Biosciences by 1.6% during the second quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock worth $44,424,000 after acquiring an additional 33,286 shares during the last quarter. Fiera Capital Corp grew its stake in IDEAYA Biosciences by 20.0% during the 3rd quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock valued at $50,011,000 after purchasing an additional 305,698 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in IDEAYA Biosciences by 4.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after purchasing an additional 50,000 shares during the last quarter. Candriam S.C.A. raised its position in shares of IDEAYA Biosciences by 10.8% in the 3rd quarter. Candriam S.C.A. now owns 1,012,967 shares of the company’s stock valued at $27,563,000 after purchasing an additional 98,567 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its stake in shares of IDEAYA Biosciences by 126.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company’s stock valued at $15,593,000 after buying an additional 414,189 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IDYA has been the subject of a number of research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd. Mizuho raised their price objective on shares of IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Tuesday, November 11th. UBS Group assumed coverage on shares of IDEAYA Biosciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush lifted their price target on IDEAYA Biosciences from $49.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Finally, Truist Financial boosted their price objective on IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Fifteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.69.

IDEAYA Biosciences Stock Performance

NASDAQ IDYA opened at $31.90 on Friday. IDEAYA Biosciences, Inc. has a one year low of $13.45 and a one year high of $39.28. The company has a 50-day simple moving average of $34.06 and a 200-day simple moving average of $30.75. The firm has a market capitalization of $2.80 billion, a PE ratio of -24.35 and a beta of 0.10.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.09. The business had revenue of $21.75 million for the quarter, compared to analyst estimates of $5.95 million. During the same quarter last year, the company earned ($1.49) EPS. IDEAYA Biosciences’s revenue was up 55.7% compared to the same quarter last year. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.